Management of colorectal cancer in pregnancy: A multimodality approach

Clinical Colorectal Cancer

Volumn 5, Issue 4, 2005, Pages 247-256

  Saif, M Wasif ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 Fluorouracil; Bevacizumad; Capecitabine; Cetuximab; Cyclooxygenase 2; Estrogen receptor; Oxaliplatin

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PROGESTERONE RECEPTOR; PROTEIN P53;

ABDOMINAL PAIN; ADENOMATOUS POLYP; ANEMIA; BREAST FEEDING; CANCER GROWTH; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; COLON CARCINOGENESIS; COLONOSCOPY; COLORECTAL CANCER; COLORECTAL SURGERY; DIAGNOSTIC ERROR; DISEASE COURSE; DRUG SAFETY; EARLY CANCER; EARLY DIAGNOSIS; ECHOGRAPHY; ENTERITIS; FAMILY HISTORY; FEMALE; GARDNER SYNDROME; GASTROINTESTINAL SYMPTOM; HUMAN; MULTIMODALITY CANCER THERAPY; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT REFERRAL; PEUTZ JEGHERS SYNDROME; PRACTICE GUIDELINE; PREGNANCY; PREGNANCY COMPLICATION; PROGNOSIS; RADIATION DOSE; RECTUM HEMORRHAGE; REVIEW; RISK FACTOR; SIGMOIDOSCOPY; TERATOGENICITY; CHEMICALLY INDUCED DISORDER; COLORECTAL TUMOR; DELIVERY; DRUG EFFECT; FERTILITY; INFERTILITY; PATIENT CARE; PRENATAL EXPOSURE; TIME;

BREAST FEEDING; COLORECTAL NEOPLASMS; DELIVERY, OBSTETRIC; FEMALE; FERTILITY; HUMANS; INFERTILITY; NEOPLASM STAGING; PATIENT CARE TEAM; PREGNANCY; PREGNANCY COMPLICATIONS, NEOPLASTIC; PRENATAL EXPOSURE DELAYED EFFECTS; TIME FACTORS;

EID: 33644843852     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.n.035     Document Type: Review

References (85)

1. Girard RM, Lamarche J, Baillot R. Carcinoma of the colon associated with pregnancy: report of a case. Dis Colon Rectum 1981; 24:473-475.
2. Cappéll MS. Colon cancer during pregnancy. Gastroenterol Clin North Am 1998; 27:225-256.
3. Bernstein MA, Madoff RD, Caushaj PF. Colon and rectal cancer in pregnancy. Dis Colon Rectum 1993; 36:172-178.
4. Nesbitt JC, Moise KJ, Sawyers JL. Colorectal carcinoma in pregnancy. Arch Surg 1985; 120:636-640.
5. Jemal A, Murray T, Ward A, et al. Cancer Statistics, 2005 [published erratum in: CA Cancer J Clin 2005; 55:259]. CA Cancer J Clin 2005; 55:10-30.
6. Walsh C, Fazio VW. Cancer of the colon, rectum, and anus during pregnancy. Gastroenterol Clin North Am 1998; 27:257-267.
7. Doll DC, Rigenberg QS, Yardro JW. Management of cancer during pregnancy. Arch Intern Med 1988; 148:2058-2064.
8. Minter A, Malik R, Ledbetter L, et al. Colon cancer in pregnancy. Cancer Control 2005; 12:196-202.
9. Woods JB, Martin JN Jr, Ingram FH, et al. Pregnancy complicated by carcinoma of the colon above the rectum. Am J Perinatol 1992; 9:102-110.
10. Isbister WH, Frasier J. Large bowel cancer in the young: a national survival study. Dis Colon Rectum 1990; 33:363-366.
11. Francavilla A, Di Leo A, Polimeno L, et al. Nuclear and cytosolic estrogen receptors in human colon carcinoma and in surrounding non cancerous colonic tissue. Gastroenterology 1987; 93:1301-1306.
12. Hendrickse CW, Jones CE, Donovan IA, et al. Oestrogen and progesterone receptors in colorectal cancer and human colonic cancer cell lines. Br J Surg 1993; 80:630-636.
13. Xu X, Thomas ML. Estrogen receptor mediated direct stimulation of colon cancer cell growth in vitro. Mol Cell Endocrinol 1994; 105:197-201.
14. Slattery ML, Samowitz WS, Holden JA. Estrogen and progesterone receptors in colon tumors. Am J Clin Pathol 2000; 113:364-368.
15. Korenaga D, Orita H, Maikawa S, et al. Relationship between hormone receptor levels and cell-kinetics in human colorectal cancer. Hepatogastroenterology 1997; 44:78-83.
16. Geelhoed GW, Alford L, Lippman ME. Biologic implications of steroid hormone receptors in cancers of the colon. South Med J 1985; 78:252-254.
17. Meggouh F, Lointier P, Saez S. Sex steroid and 1,25-dihydroxyvitamin D3 receptors in human colorectal adenocarcinoma and normal mucosa. Cancer Res 1991; 51:1227-1233.
18. Singh S, Sheppard MC, Langman MJ. Sex differences in the incidence of colorectal cancer: an exploration of oestrogen and progesterone receptors. Gut 1993; 34:611-615.
19. Haffner R, Oren M. Biochemical properties and biological effects of p53. Curr Opin Genet Dev 1995; 5:84-90.
20. Levine AJ. The p53 tumor-suppressor gene. N Engl J Med 1992; 326:1350-1352.
21. Rojansky N, Shushan A, Livni N, et al. Pregnancy associated with colon carcinoma overexpressing p53. Gynecol Oncol 1997; 64:516-520.
22. Bazan V, Migliavacca M, Tubiolo C, et al. Have p53 gene mutations and protein expression a different biological significance in colorectal cancer? J Cell Physiol 2002; 191:237-246.
23. Kitoh T, Nishimura S, Fukuda S, et al. The incidence of colorectal cancer during pregnancy in Japan: report of two cases and review of Japanese cases. Am J Perinatol 1998; 15:165-171.
24. Subongkot S, Frame D, Leslie W, et al. Selective cyclooxygenase-2 inhibition: a target in cancer prevention and treatment. Pharmacotherapy 2003; 23:9-28.
25. Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107:1183-1188.
26. Lim H, Paria BX, Das SK, et al. Multiple female reproductive failures in cyclooxygenase 2-deficient mice. Cell 1997; 91:197-208.
27. Majerus, PW. Prostaglandins: critical roles in pregnancy and colon cancer. Curr Biol 1998; 8:R87-R89.
28. Williams CS, Smalley W, DuBois RN. Aspirin use and potential mechanisms for colorectal cancer prevention. J Clin Invest 1997; 100:1325-1329.
29. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121:241-246.
30. Balthazer EJ, Megibow AJ, Hulnick D, et al. Carcinoma of the colon: detection and preoperative staging by CT. AJR Am J Roentgenol 1988; 150:301-306.
31. Cappel MS. The safety of gastrointestinal endoscopy in high risk patients. Dig Dis 1996; 14:228-244.
32. Melmed AD. Anesthesia principles and techniques in pregnancy. In: Cherr ST, Merkatz IR eds. Complications of pregnancy: medical, surgical, gynecologic, psychosocial, and perinatal. 4th ed. Baltimore: Williams & Wilkins; 1991:732-764.
33. Dark DS, Campbell DR, Wesselius LJ. Arterial oxygen desaturation during gastrointestinal endoscopy. Am J Gastroenterol 1990; 85:1317-1321.
34. Cappell MS, Colon VJ, Sidhom OA. A Study of eight medical centers of the safety and clinical efficacy of esophagogastroduodenoscopy in 83 pregnant females with follow-up of fetal in 83 pregnant females with follow-up of fetal outcome and with comparison to control groups. Am J Gastroenterol 1996; 91:348-354.
35. Lamerz R, Reuder H. Significance of CEA determination in patients with cancer of the colon-rectum and the mammary gland in comparison to physiological states in connection with pregnancy. Bull Cancer 1976; 63:575-586.
36. Fletcher RH. Carcinoembryonic antigen. Ann Intern Med 1986; 104:66-73.
37. Brent RL. Radiation teratogenesis. Tetralogy 1980; 21:281-298.
38. Brent RL. The effect of embryonic and fetal exposure to x-ray, microwaves, and ultrasound: counseling the pregnant and nonpregnant patient about these risks. Semin Oncol 1989; 16:347-368.
39. Saween S, Goldman S, Shah K, et al. Acute non-traumatic maternal illnesses in pregnancy: imaging approaches. Emerg Radiol 2005; 11:199-212.
40. Wagner LK, Lester RG, Saldana LR. The diagnostic radiations and their mechanisms for injury in exposure of the pregnant patient to diagnostic radiations. In: Wagner LK, Lester RG, Saldana LR, et al. Exposure of the pregnant patient to diagnostic radiations: a guide to medical management. 2nd ed. Madison, WI: Medical Physics Publishing; 1997:3-34.
41. Pates JA, Twickler DM. The use of radiologic modalities to diagnose infection in pregnancy. Clin Perinatol 2005; 32:789-802.
42. Lees WR. Ultrasound of liver and spleen. In: Sutton D, Isherwood I, Forbes W. et al, eds. A textbook of radiology and imaging. 5th ed. Edinburgh: Churchill Livingstone; 1993:969-981.
43. Nies C, Leppek R, Sitter H, et al. Prospective evaluation of different diagnostic techniques for the detection of liver metastases at time of primary resection of colorectal carcinoma. Eur J Surg 1996; 162:811-816.
44. Seidman DS, Heyman Z, Ben-Ari G, et al. Use of magnetic imaging in pregnancy to diagnose intussusception induced by colon cancer. Obstet Gynecol 1992; 79:822-823.
45. Levendecker JR, Gorengaut V, Brown JJ. MR imaging of maternal diseases of the abdomen and pelvis during pregnancy and the immediate postpartum period. Radiographics 2004; 24:1301-1316.
46. Knoepp LF Jr, Ray JE, Overby I. Ovarian metastases from colorectal carcinoma. Dis Colon Rectum 1973; 16:305-311.
47. Mason MH, Kovalcik PJ. Ovarian metastases from colon carcinoma. J Surg Oncol 1981; 17:33-38.
48. Pitluk H, Poticha SM. Carcinoma of the colon and rectum in patients less than 40 years of age. Surg Gynecol Obstet 1983; 157:335-337.
49. Fenig E, Mishaeli M, Kalish Y, et al. Pregnancy and radiation. Cancer Treat Rev 2001; 27:1-7.
50. Ngu SL, Duval P, Collins C. Foetal radiation dose in radiotherapy for breast cancer. Australas Radiol 1992; 36:321-322.
51. Fleshman JW, Myerson RJ. Adjuvant radiation therapy for adenocarcinoma of the rectum. Surg Clin North Am 1997; 77:15-25.
52. Lashrop JC. Malignant pelvic lymphoma. Obstet Gynecol 1967; 30:137-145.
53. Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5:283-291.
54. Martin MJ. Current stage-specific chemotherapeutic options in colon cancer. Expert Rev Anticancer Ther 2005; 5:695-704.
55. MacDonald JS. Adjuvant chemotherapy for colon cancer. Cancer J Clin 1997; 47:243-256.
56. Moertel CG, Fleming TR, MacDonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-326.
57. Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000; 343:905-914.
58. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
59. Andre T, Boni C, Mounedji-Boudiaf L, et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators. N Engl J Med 2004; 350:2343-2351.
60. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.
61. Saltz LB, Meropol NJ, Loehrer PJ Sr, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
62. Saif MW. Capecitabine versus continuous-infusion 5-fluorouracil for colorectal cancer: a retrospective efficacy and safety comparison. Clin Colorectal Cancer 2005; 5:89-100.
63. Chaube S, Murphy ML. The teratogenic effects of the recent drug active in cancer chemotherapy. In Whoollam DHM, ed. Advances in teratology, vol. 3, New York: Academic Press, 1968:181-237.
64. Shuey DL, Zucker RM, Elstein KH, et al. Fetal anemia following maternal exposure to 5-fluorouracil in the rat. Teratology 1994; 49:311-319.
65. Shuey DL, Lau C, Logsdon TR, et al. Biologically based dose-response modeling in developmental toxicology: biochemical and cellular sequelae of 5-fluorouracil exposure in the development in the rat. Toxicol Appl Pharmacol 1994; 126:129-144.
66. Boike GM, Deppe G, Young JD, et al. Chemotherapy in a pregnant rat model. 2.5-fluorouracil: nonlinear kinetics and placental transfer. Gynecol Oncol 1989; 34:191-194.
67. Dagg, CP. Sensitive stages for the production of developmental abnormalities in mice with 5-fluorouracil. Am J Anat 1960; 106:89-96.
68. Wilson, JG. Use of rhesus monkeys in the teratological studies. Fed Proc 1972; 30:104-109.
69. Wilson, JG. Abnormalities of intrauterine development in nonhuman primates. Acta Endocrinol 1972; 71:261-292.
70. Zelmlickis D, Lishner M, Degendorfer P, et al. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 1992; 152:573-576.
71. Stephens TD, Golbus MS, Miller TR, et al. Multiple congenital anomalies in a fetus exposed to 5-fluorouracil during the first trimester. Am J Obstet Gynecol 1980; 137:747-749.
72. Dreicer R, Love RR. High total dose 5-fluorouracil treatment during pregnancy. Wis Med J 1991; 90:582-583.
73. Turchi JJ, Villasis C. Anthracyclines in the treatment of malignancy in pregnancy. Cancer 1988; 61:435-440.
74. Stadler HE, Knowles J. Fluorouracil in pregnancy: effect on the neonate. JAMA 1971; 217:214-215.
75. Eloxatin [package insert]. New York: Sanofi-Synthelabo, Inc; 2002.
76. Camptosar [package insert]. New York: Pfizer Oncology; 2002.
77. Erbitux [package insert]. Princeton, NJ: ImClone Systemsm Inc; 2004.
78. Xeloda [package insert]. Nutley, NJ: Roche Pharmaceuticals; 2003
79. Zemlickis D, Lishner M, Degendorfer P, et al. Fetal outcome after in utero exposure to cancer chemotherapy. Arch Intern Med 1992; 152:573-576.
80. Blatt J, Poplack DG, Sherins RJ. Testicular function in boys after chemotherapy for acute lymphoblastic leukemia. N Engl J Med 1981; 304:1121-1124.
81. Aviles A, Niz J. Long-term follow up of children born to mothers with acute leukemia during pregnancy. Med Pediatr Oncol 1988; 16:3-6.
82. Aviles A, Diaz-Marqueo JC, Talavera A, et al. Growth and development of children of mothers treated with chemotherapy during pregnancy: current status of 43 children. Am J Hematol 1991; 36:243-248.
83. Aviles A, Diaz-Marqueo JC, Terras V, et al. Non-Hodgkin's lymphoma and pregnancy. Gynecology 1990; 37:335-337.
84. Blatt J, Mulvihill JJ, Ziegler JL, et al. Pregnancy outcome following cancer chemotherapy. Am J Med 1980; 69:828-832.
85. Chan YK, Ngai SE, Lao TT. Colon cancer in pregnancy: a case report. J Reprod Med 1999; 44:733-736.